Regenerative medicine: Clinical relevance, implications and limitations of the stem cell-based therapies

Cell Cycle

Volumn 7, Issue 21, 2008, Pages 3292-3293

  Glinsky, Gennadi V ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Cancer metastasis; Embryonic stem cells; Regenerative medicine; Stemness and cancer genomes; Therapy resistant cancers; Translational and functional genomics

Indexed keywords

BONE MARROW CELL; CANCER RESISTANCE; CANCER THERAPY; EDITORIAL; EMBRYONIC STEM CELL; FUNCTIONAL GENOMICS; GENETIC ENGINEERING; METASTASIS; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

EID: 55849088323     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.21.6973     Document Type: Editorial

References (25)

1. Glinsky GV. Regenerative medicine: Evidence for remarkable healing power of adult (somatic) stem cells. Cell Cycle 2008; 7:1697.
2. Amoh Y, Li L, Katsuoka K, Hoffman RM. Multipotent hair follicle stem cells promote repair of spinal cord injury and recovery of walking function. Cell Cycle 2008; 7:1865-9.
3. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318:1917-20.
4. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-76.
5. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-72.
6. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451:141-6.
7. Glinsky GV. Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 2005; 4:1171-5.
8. Glinsky GV, Glinskii AB, Berezovskaya O. Microarray analysis identifies a death-fromcancer signature predicting therapy failure in patients with multiple types of cancer. Journal of Clinical Investigation 2005; 115:1503-21.
9. Glinsky GV. Genomic models of metastatic cancer: Functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 2006; 5:1208-16.
10. Berezovska OP, Glinskii AB, Yang Z, Li X-M, Hoffman RM, Glinsky GV. Essential role of the Polycomb Group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006; 5:1886-901.
11. Glinsky GV. Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers. Stem Cells Reviews 2007; 3:79-93.
12. Glinsky GV. "Stemness" genomics law governs clinical behavior of human cancer: Implications for decision making in disease management. Journal of Clinical Oncology 2008; 26:2846-53.
13. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yul W, Berman DM, Jenuwein T, Pruitt K, Sharkis SJ, Watkins DN, Herman JG and Baylin SB. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nature Genetics 2007; 39:237-42.
14. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I and Laird PW. Epigenetic stem cell signature in cancer. Nature Genetics 2007; 39:157-8.
15. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, Bergman Y, Simon I and Cedar H. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nature Genetics 2007; 39:232-6.
16. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358:1118-28.
17. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67:10657-63.
18. Laurent LC, Chen J, Ulitsky I, Mueller FJ, Lu C, Shamir R, Fan JB, Loring JF. Comprehensive microRNA profiling reveals a unique human embryonic stem cell signature dominated by a single seed sequence. Stem Cells 2008; 26:1506-16.
19. Bibikova M, Laurent LC, Ren B, Loring JF, Fan JB. Unraveling epigenetic regulation in embryonic stem cells. Cell Stem Cell 2008; 2:123-4.
20. Glinsky GV. Phenotype-defining functions of multiple non-coding RNA pathways. Cell Cycle 2008; 7:1630-9.
21. Glinsky GV. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal compinenets of nuclear import pathway. Cell Cycle 2008; 7:2570-83.
22. Cogle CR, Theise ND, Fu D, Ucar D, Lee S, Guthrie SM, Lonergan J, Rybka W, Krause DS, Scott EW. Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry. Stem Cells 2007; 25:1881-7.
23. Golfinopouloss V, Pentheroudakis G, Kamakari S, Metaxa-Mariatou V, Pavlidis N. Donor-derived breast cancer in a bone marrow transplantation recipient. Breast Cancer Res Treat 2008; [Epub ahead of print].
24. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, et al. Gastric cancer originating from bone marrow derived cells. Science 2004; 306:1568-71.
25. Rizvi AZ, Swain JR, Davies PS, Bailey AS, Decker AD, Willenbring H, et al. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. PNAS USA 2006; 103:6321-5.